Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates.
Understanding the complex interactions of retroviral proteases with their ligands is an important scientific challenge in efforts to achieve control of retroviral infections. Development of drug resistance because of high mutation rates and extensive polymorphisms causes major problems in treating the deadly diseases these viruses cause, and prompts efforts to identify new strategies. Here we report a comprehensive analysis of the interaction of 63 retroviral proteases from nine different viral species with their substrates and inhibitors based on publicly available data from the past 17years of retroviral research. By correlating physico-chemical descriptions of retroviral proteases and substrates to their biological activities we constructed a highly statistically valid 'proteochemometric' model for the interactome of retroviral proteases. Analysis of the model indicated amino acid positions in retroviral proteases with the highest influence on ligand activity and revealed general physicochemical properties essential for tight binding of substrates across multiple retroviral proteases. Hexapeptide inhibitors developed based on the discovered general properties effectively inhibited HIV-1 proteases in vitro, and some exhibited uniformly high inhibitory activity against all HIV-1 proteases mutants evaluated. A generalized proteochemometric model for retroviral proteases interactome has been created and analysed in this study. Our results demonstrate the feasibility of using the developed general strategy in the design of inhibitory peptides that can potentially serve as templates for drug resistance-improved HIV retardants.
Kontijevskis
Aleksejs
A
Department of Pharmaceutical Biosciences, Uppsala University, Husargatan 3, SE-75124, Uppsala, Sweden.
Petrovska
Ramona
R
Yahorava
Sviatlana
S
Komorowski
Jan
J
Wikberg
Jarl E S
JE
D000595:Amino Acid Sequence; D019295:Computational Biology / Q000379:methods*; D015195:Drug Design; D024881:Drug Resistance, Bacterial; D015497:HIV-1 / Q000201:enzymology; D008954:Models, Biological; D009154:Mutation; D010447:Peptide Hydrolases / Q000235:genetics / Q000378:metabolism*; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011480:Protease Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D011485:Protein Binding; D012190:Retroviridae / Q000201:enzymology*; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*
D010455:Peptides; D011480:Protease Inhibitors; D014764:Viral Proteins; D010447:Peptide Hydrolases